Blockade of endothelin receptors markedly reduces atherosclerosis in LDL receptor deficient mice: role of endothelin in macrophage foam cell formation

被引:65
作者
Babaei, S
Picard, P
Ravandi, A
Monge, JC
Lee, TC
Cernacek, P
Stewart, DJ
机构
[1] St Michaels Hosp, Terrence Donnelly Heart Ctr, Div Cardiol, Toronto, ON M5B 1W8, Canada
[2] Univ Toronto, Dept Med, Toronto, ON, Canada
[3] Univ Toronto, Lab Med & Pathobiol, Toronto, ON, Canada
[4] Montreal Heart Inst, Dept Lab Med, Montreal, PQ H1T 1C8, Canada
基金
英国医学研究理事会;
关键词
atherosclerosis; cholesterol; endothelins; macrophages; receptors;
D O I
10.1016/S0008-6363(00)00169-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: We evaluated the direct effects of long-term blockade of ETA and ETB receptors using a mixed endothelin (ET) receptor antagonist, LU224332, in the low density lipoprotein receptor (LDL-R) knockout mouse model of atherosclerosis. Methods: Four groups of LDL-R deficient mice were studied: control mice fed normal chow (group I); mice fed a high cholesterol (HC, 1.25%) diet alone (group II), HC fed animals treated with LU224332 (group UI); and mice fed normal chow treated with the LU compound (group IV). All treatments were continued for 8 weeks at which time the animals were sacrificed and the aortae were removed and stained with oil red O. Atherosclerotic area (AA) was determined by quantitative morphometry and normalized relative to total aortic area (TA). Results: Cholesterol feeding resulted in a marked increased in total plasma cholesterol (similar to 15 fold) and widespread aortic atherosclerosis (AA/TA: group I: 0.013+/-0.007; group II: 0.33+/-0.11; P<0.001). Atherosclerotic lesions were characterized by immunohistochemistry as consisting mainly of macrophages which also showed high levels of ET-1 expression. Treatment with ET antagonist significantly reduced the development of atherosclerosis (AA/TA: group III: 0.19+/-0.07, P<0.01 vs. group II), without altering plasma. cholesterol levels and blood pressure. The direct effect of LU224332 on macrophage activation and foam-cell formation was determined in vitro using a human macrophage cell line, THP-1. Treatment of the THP-1 cells with LU224332 significantly reduced cholesterol ester and triacylglycerol accumulation and foam-cell formation on exposure to oxidized LDL (P<0.01 and P<0.05, respectively). Conclusion: We conclude that a nonselective ET receptor antagonist substantially inhibited the development of atherosclerosis in a genetic model of hyperlipidemia, possibly by inhibiting macrophage foam-cell formation, suggesting a role for these agents in the treatment and prevention of atherosclerotic vascular disease. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:158 / 167
页数:10
相关论文
共 52 条
[1]  
ACHMAD TH, 1992, BIOCHEM BIOPH RES CO, V189, P994
[2]  
Aji W, 1997, CIRCULATION, V95, P430
[3]   Endothelin-1 causes a prolonged protein kinase C activation and acts as a co-mitogen in vascular smooth muscle cells [J].
Assender, JW ;
Irenius, E ;
Fredholm, BB .
ACTA PHYSIOLOGICA SCANDINAVICA, 1996, 157 (04) :451-460
[4]   DIFFERENT LOCALIZATION OF ET(A) AND ET(B) RECEPTORS IN THE HYPERPLASTIC VASCULAR WALL [J].
AZUMA, H ;
HAMASAKI, H ;
SATO, J ;
ISOTANI, E ;
OBAYASHI, S ;
MATSUBARA, O .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1995, 25 (05) :802-809
[5]   Endothelin receptors in human coronary artery and aorta [J].
Bacon, CR ;
Davenport, AP .
BRITISH JOURNAL OF PHARMACOLOGY, 1996, 117 (05) :986-992
[6]   Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice [J].
Barton, M ;
Haudenschild, CC ;
D'Uscio, LV ;
Shaw, S ;
Münter, K ;
Lüscher, TF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (24) :14367-14372
[7]   Chronic endothelin receptor antagonism preserves coronary endothelial function in experimental hypercholesterolemia [J].
Best, PJM ;
McKenna, CJ ;
Hasdai, D ;
Holmes, DR ;
Lerman, A .
CIRCULATION, 1999, 99 (13) :1747-1752
[8]   LIPOPROTEIN RECEPTORS IN THE LIVER - CONTROL SIGNALS FOR PLASMA-CHOLESTEROL TRAFFIC [J].
BROWN, MS ;
GOLDSTEIN, JL .
JOURNAL OF CLINICAL INVESTIGATION, 1983, 72 (03) :743-747
[9]  
Bult H, 1996, MOL MED TODAY, V2, P510
[10]  
Cernacek P, 1998, CLIN CHEM, V44, P1666